Formulation and Evaluation of Olopatadine Hydrochloride Opthalmic Solution

Olopatadine Hydrochloride is a selective histamine H1-receptor antagonist and mast cell stabilizer widely used in the treatment of allergic conjunctivitis. The present study aimed to formulate and evaluate a sterile ophthalmic solution of Olopatadine Hydrochloride with enhanced stability, safety, and patient compliance. The ophthalmic solution was prepared using suitable excipients, including buffering agents, tonicity adjusters, preservatives, and viscosity enhancers to achieve optimal physicochemical properties and ocular compatibility.

Olopatadine Hydrochloride, Ophthalmic Solution, Allergic Conjunctivitis, Sterility

1. Abelson MB, Gomes PJ. Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing. Expert Opin Pharmacother. 2008;4(4):453-461. [Google Scholar] [Crossref]

2. Rosenwasser LJ, O'Brien T, Weyne J. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research. Curr Med Res Opin. 2005;21(9):1377-1387. [Google Scholar] [Crossref]

3. Kaliner MA, Oppenheimer J, Farrar JR. Comprehensive review of olopatadine: the molecule and its clinical entities. Allergy Asthma Proc. 2010;31(2):112-119. [Google Scholar] [Crossref]

4. Watanabe M, Kodama H, Hasegawa K, Itoh K. Pharmacological profile and clinical efficacy of olopatadine hydrochloride ophthalmic solution (Patanol 0.1% ophthalmic solution). Nihon Yakurigaku Zasshi. 2007;130(3):221-231. [Google Scholar] [Crossref]

5. McGill JI. A review of the use of olopatadine in allergic conjunctivitis. Int Ophthalmol. 2004;25(3):171-179. [Google Scholar] [Crossref]

6. Abelson MB. A review of olopatadine for the treatment of ocular allergy. Expert Opin Pharmacother. 2004;5(9):1979-1994. [Google Scholar] [Crossref]

7. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12(3):348-360. [Google Scholar] [Crossref]

8. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev. 2005;57(11):1595-1639. [Google Scholar] [Crossref]

9. Kaur IP, Kanwar M. Ocular preparations: the formulation approach. Drug Dev Ind Pharm. 2002;28(5):473-493. [Google Scholar] [Crossref]

10. Agarwal P, Rupenthal ID. Modern approaches to ocular drug delivery. Drug Discov Today. 2013;18(17-18):823-833. [Google Scholar] [Crossref]

11. Yellepeddi VK, Palakurthi S. Recent advances in topical ocular drug delivery. J Ocul Pharmacol Ther. 2016;32(2):67-82. [Google Scholar] [Crossref]

12. Jain GK, Jain N. Ocular drug delivery systems: an overview. Drug Deliv. 2014;21(4):247-262. [Google Scholar] [Crossref]

13. Rathore AS, Winkle H. Quality by Design for biopharmaceuticals and pharmaceutical products. Nat Biotechnol. 2009;27(1):26-34. [Google Scholar] [Crossref]

14. Schoenwald RD. Ocular drug delivery: pharmacokinetic considerations. Clin Pharmacokinet. 1990;18(4):255-269. [Google Scholar] [Crossref]

15. Abelson MB, Spangler DL, Epstein AB, Mah FS, Crampton HJ. Efficacy and safety of olopatadine ophthalmic solution 0.1% in allergic conjunctivitis. Surv Ophthalmol. 2000;44(Suppl 1):S113-S120. [Google Scholar] [Crossref]

16. Leonardi A, Castegnaro A, Valerio AL, Lazzarini D. Epidemiology of allergic conjunctivitis: clinical appearance and treatment patterns. Allergy. 2015;70(9):1053-1058. [Google Scholar] [Crossref]

17. Berdy GJ, Stoppel JO, Epstein AB. Long-term efficacy and safety of olopatadine hydrochloride ophthalmic solution 0.1%. Clin Ther. 2000;22(4):518-526. [Google Scholar] [Crossref]

18. Yanni JM, Miller ST, Gamache DA, et al. Comparative ocular pharmacology of olopatadine and ketotifen in allergic conjunctivitis models. Arch Ophthalmol. 1999;117(5):643-647. [Google Scholar] [Crossref]

19. Schoenwald RD. Ocular drug delivery: pharmacokinetic considerations. Clin Pharmacokinet. 1990;18(4):255-269. [Google Scholar] [Crossref]

20. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev. 2005;57(11):1595-1639. [Google Scholar] [Crossref]

21. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12(3):348-360. [Google Scholar] [Crossref]

22. Mitra AK, Cholkar K, Mandal A. Emerging nanotechnologies for ocular drug delivery. J Control Release. 2016;219:526-542. [Google Scholar] [Crossref]

23. Rathore AS, Winkle H. Quality by Design for biopharmaceuticals and pharmaceutical products. Nat Biotechnol. 2009;27(1):26-34. [Google Scholar] [Crossref]

24. Ahmed I, Patton TF. Importance of formulation factors in ophthalmic drug products. Int J Pharm. 1985;28(1):1-10. [Google Scholar] [Crossref]

25. Kaur IP, Kanwar M. Ocular preparations: the formulation approach. Drug Dev Ind Pharm. 2002;28(5):473-493. [Google Scholar] [Crossref]

26. Yellepeddi VK, Palakurthi S. Recent advances in topical ocular drug delivery. J Ocul Pharmacol Ther. 2016;32(2):67-82. [Google Scholar] [Crossref]

27. Agarwal P, Rupenthal ID. Modern approaches to ocular drug delivery. Drug Discov Today. 2013;18(17-18):823-833. [Google Scholar] [Crossref]

28. Jain GK, Jain N. Ocular drug delivery systems: an overview. Drug Deliv. 2014;21(4):247-262. [Google Scholar] [Crossref]

29. Deshpande SG, Shirolkar SV. Development and evaluation of ophthalmic formulations: a review. Int J Pharm Sci Rev Res. 2011;10(1):112-118. [Google Scholar] [Crossref]

30. Abelson MB, Gomes PJ. Olopatadine hydrochloride ophthalmic solution 0.2%: a review of its efficacy and safety in the management of allergic conjunctivitis. Clin Ther. 2008;30(11):1958-1972. [Google Scholar] [Crossref]

31. McGill JI. A review of olopatadine for the treatment of ocular allergy. Curr Med Res Opin. 2004;20(5):717-726. [Google Scholar] [Crossref]

32. Rosenwasser LJ, O'Brien TP, Weyne J. Mast cell stabilization and antihistaminic effects of olopatadine ophthalmic solution. Curr Med Res Opin. 2005;21(9):1377-1387. [Google Scholar] [Crossref]

33. Uchio E. Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops. Clin Ophthalmol. 2008;2(3):525-531. [Google Scholar] [Crossref]

34. Kaliner MA, Oppenheimer J, Farrar JR. Olopatadine: a comprehensive review of its role in allergic diseases. Allergy Asthma Proc. 2010;31(2):112-119. [Google Scholar] [Crossref]

35. Watanabe M, Kodama H, Hasegawa K, Itoh K. Pharmacological profile and clinical efficacy of olopatadine hydrochloride ophthalmic solution. Nihon Yakurigaku Zasshi. 2007;130(3):221-231. [Google Scholar] [Crossref]

36. Ousler GW, Wilcox KA, Gupta G, Abelson MB. An evaluation of the efficacy of olopatadine ophthalmic solution in allergic conjunctivitis. Allergy Asthma Proc. 2004;25(6):435-438. [Google Scholar] [Crossref]

37. Vogelson CT, Abelson MB, Pasquine TA, Gross RD. Clinical efficacy of olopatadine ophthalmic solution in seasonal allergic conjunctivitis. Adv Ther. 2004;21(6):413-420. [Google Scholar] [Crossref]

38. Berdy GJ, Spangler DL, Bensch GW. A comparison of olopatadine hydrochloride and ketotifen fumarate ophthalmic solutions in allergic conjunctivitis. Clin Ther. 2002;24(6):918-929. [Google Scholar] [Crossref]

39. Leonardi A, Busca F, Motterle L, Cavarzeran F, Fregona IA, Plebani M. Case series evaluating olopatadine in ocular allergy management. Eur J Ophthalmol. 2015;25(4):302-307. [Google Scholar] [Crossref]

40. Cholkar K, Patel A, Vadlapudi AD, Mitra AK. Novel strategies for anterior segment ocular drug delivery. J Ocul Pharmacol Ther. 2013;29(2):106-123. [Google Scholar] [Crossref]

41. Gaudana R, Jwala J, Boddu SHS, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res. 2009;26(5):1197-1216. [Google Scholar] [Crossref]

42. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. World J Pharmacol. 2013;2(2):47-64. [Google Scholar] [Crossref]

43. Barar J, Javadzadeh AR, Omidi Y. Ocular novel drug delivery: impacts of membranes and barriers. Expert Opin Drug Deliv. 2008;5(5):567-581. [Google Scholar] [Crossref]

44. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58(11):1131-1135. [Google Scholar] [Crossref]

45. Cholkar K, Dasari SR, Pal D, Mitra AK. Eye: anatomy, physiology and barriers to drug delivery. In: Mitra AK, editor. Ocular Transporters and Receptors. New York: Woodhead Publishing; 2013. p. 1-36. [Google Scholar] [Crossref]

46. Sultana Y, Aqil M, Ali A. Ocular inserts for controlled delivery of drugs: a review. Acta Pharm. 2006;56(1):1-9. [Google Scholar] [Crossref]

47. Saettone MF, Salminen L. Ocular inserts for topical delivery. Adv Drug Deliv Rev. 1995;16(1):95-106. [Google Scholar] [Crossref]

48. Lang JC. Ocular drug delivery conventional ocular formulations. Adv Drug Deliv Rev. 1995;16(1):39-43. [Google Scholar] [Crossref]

49. Gaudana R, Pegazi A, Mahaling B, Mitra AK. Advances in ocular drug delivery. Ther Deliv. 2015;6(4):441-456. [Google Scholar] [Crossref]

50. Rajoriya V, Gupta R. Folate functionalized nanostructured lipid carriers of paclitaxel for site specific A549 lung adenocarcinoma targeting. BioNanoSci. 2025;15:503. doi:10.1007/s12668-025-02133-9. [Google Scholar] [Crossref]

51. Rajoriya V, Gupta R. Folate anchored nanostructured lipid carrier for lung A549 adenocarcinoma cell targeting. J Neonatal Surg. 2025;14(32S):3272-3280. Available from: https://www.jneonatalsurg.com [Google Scholar] [Crossref]

52. Rajoriya V, Gupta R, Vengurlekar S, Jain SK. Folate conjugated nano-lipid construct of paclitaxel for site-specific lung squamous carcinoma targeting. Int J Pharm. 2025;672:125312. doi:10.1016/j.ijpharm.2025.125312. [Google Scholar] [Crossref]

53. Rajoriya V, Rajoriya V, Gupta R, Gupta S, Jain SK. Analyzing terpenes' role in cancer treatment. Hershey (PA): IGI Global Scientific Publishing; 2025. p. 87-106. [Google Scholar] [Crossref]

54. Rajoriya V, Gupta R, Vengurlekar S, Singh US. Nanostructured lipid carriers (NLCs): A promising candidate for lung cancer targeting. Int J Pharm. 2024;655:123986. doi:10.1016/j.ijpharm.2024.123986. [Google Scholar] [Crossref]

55. Rajoriya V, Rajoriya V, Thakur AS, Sharma Y, Parashar R, Chourasiya S, Patel K, Yadav P, Mishra A. Formulation development, optimization and characterization of folate conjugated solid lipid nanoparticle (FC-SLNs) for effective lung cancer targeting. Int J Novel Res Dev. 2024;9(7):e180-e187. [Google Scholar] [Crossref]

56. Tomar S, Rajoriya V, Sahu P, Agarwal S, Vyas SP, Kashaw SK. Multifunctional nanoparticles for organelle-specific targeted drug delivery in cancer therapy. Curr Nanomed. 2022;12(3):191-203. doi:10.2174/2468187313666221219150315. [Google Scholar] [Crossref]

57. Rajoriya V, Kashaw V, Kashaw SK. Folate conjugated solid lipid nanoparticle: formulation development, optimization, and characterization. Curr Nanomed. 2021;11(3):186-199. doi:10.2174/2468187311666211201111858. [Google Scholar] [Crossref]

58. Rathore S, Rajoriya V, Kushwaha V, Jain S, Kashaw SK. Preparation and characterization of 5-fluorouracil loaded nanogels for skin cancer treatments: in vitro drug release, cytotoxicity and cellular uptake analysis. Curr Nanomed. 2021;11(2):127-138. doi:10.2174/2468187311666210301112644. [Google Scholar] [Crossref]

59. Bilthariya U, Jain N, Rajoriya V, Jain AK. Folate-conjugated albumin nanoparticles for rheumatoid arthritis-targeted delivery of etoricoxib. Drug Dev Ind Pharm. 2015;41(1):95-104. doi:10.3109/03639045.2013.850705. [Google Scholar] [Crossref]

60. Mishra D, Jain N, Rajoriya V, Jain AK. Glycyrrhizin conjugated chitosan nanoparticles for hepatocyte-targeted delivery of lamivudine. J Pharm Pharmacol. 2014;66(8):1082-1093. doi:10.1111/jphp.12235. [Google Scholar] [Crossref]

61. Sahu PK, Mishra DK, Jain N, Rajoriya V, Jain AK. Mannosylated solid lipid nanoparticles for lung-targeted delivery of paclitaxel. Drug Dev Ind Pharm. 2015;41(4):640-649. doi:10.3109/03639045.2014.891130. [Google Scholar] [Crossref]

62. Yadav A, Koshti D, Parashar R, Rajoriya V, Sharma Y, Thakur AS. Formulation and evaluation of orodispersible tablets of Galantamine hydrochloride for effective treatment of Alzheimer. Int J Res Innov Appl Sci. 2026;11(3):1539-1561. doi:10.51584/IJRIAS.2026.11030119. [Google Scholar] [Crossref]

• Development and Evaluation of Floating Alginate Beads of Esomeprazole
• Determination of pKa Value for Ranolazine and Atenolol Using UV Spectroscopy
• The Science of Sustained-Release Medications
• Development of Proteomics in Clinical Medicine
• Advances on Quinoline Derivatives: A Review of Synthesis and Biological Activities